Pharmacological screening identified promising combination partners in marginal zone lymphoma models with secondary resistance to BTK and PI3K inhibitors. (October 2022) - Arribas, A.; Vultaggio, S.; Andronache, A.; Robusto, M.; Fancelli, D.; Cannas, E.; Spriano, F.; Tarantelli, C.; Rossi, D.; Zucca, E.; Stathis, A.; Varasi, M.; et al.